QLE / HALEU: Structuring ASPI as an Options Book on Advanced Nuclear Fuel
2/18/26
SEQH Capital Research
QLE / HALEU: Structuring ASPI as an Options Book on Advanced Nuclear Fuel
Tear Sheet – February 18, 2026
Why This Report Exists
Most ASPI analysis treats the company as a monolith. This report separates the two economic engines, stable isotopes (ASPI OpCo) and nuclear fuel (QLE subsidiary), and values ASPI’s HALEU exposure as a structured options book: a perpetual royalty call plus a levered equity call on the HALEU TAM.
The QLE Structure
ASPI has separated “advanced nuclear fuel” into Quantum Leap Energy (QLE), a wholly owned subsidiary targeting a separate Nasdaq listing (S-1 confidentially filed).
ASPI retains two economic levers post-spin:
10% perpetual royalty on all QLE revenues (no further ASPI capex required).
Residual equity stake in QLE (assumed ~60% retained).
100% of non-nuclear-fuel isotope economics (C-14, Si-28, Mo-100, etc.) stay with ASPI.
QLE relationships signed: TerraPower, Fermi America, Necsa.
The TerraPower Contract: The Financial Anchor
Pelindaba HALEU facility (South Africa):
Capacity: ~15 MTU/year using ASPI’s QE/ASP technologies.
Timeline: Initial HALEU production targeted 2027.
Financing: TerraPower term loan plus non-dilutive project-style financing in discussion.
Offtake:
10-year supply agreement covering up to 150 MT of HALEU (2028–2037).
At 18,000–20,000 dollars per kg, implied nominal contract value is 2.7–3.0 billion dollars.
One plant captures ~30% of the NIA’s 2035 base case HALEU demand (~50 MTU/year).
Plant Economics
QE cost advantage vs. centrifuge baseline:
Centrifuge HALEU all-in cost: ~23,725 dollars per kgU (NIA model).
QE single-stage cost at 75 dollars per SWU: ~15,528 dollars per kgU, a 35% reduction.
At HALEU market prices of 18,000–20,000 dollars per kg, gross margins of 10–25%.
Annual gross profit at 15,000 kg/year output: 21–67.5 million dollars.
10-year cumulative gross profit: 210–675 million dollars (before discounting).
TerraPower Contract NPV to QLE
At 20,000 dollars per kg and 15,000 kg/year over 10 years (3.0 billion nominal):
Bear (5% EBIT margin): ~76 million dollars NPV at 10% discount.
Base (15% EBIT margin): ~228 million dollars NPV.
Bull (25% EBIT margin): ~381 million dollars NPV.
This is from the TerraPower contract alone, excludes all future contracts and products.
Embedded Value to ASPI
From TerraPower contract alone:
Royalty (10% of revenue): 30 million dollars per year, 10-year NPV of ~154 million dollars.
Retained equity (~60% of base-case QLE EV of 200M): ~120 million dollars.
Combined embedded value to ASPI: approximately 274 million dollars, covering a substantial portion of ASPI’s early 2025 market cap of ~410 million dollars.
The Options Framework
Royalty = Perpetual call on QLE revenues. Zero-strike option requiring no further ASPI capex. Payoff is 10% of QLE top-line regardless of QLE’s margins or capital structure. Primary risk is QLE execution.
Retained equity = Levered call on HALEU TAM. Value increases non-linearly as HALEU demand grows and QLE secures additional contracts beyond Pelindaba. Classic call option payoff profile with convex upside.
Key Risks
QE has not been demonstrated on uranium at commercial scale. Engineering gap from Yb-176 to U-235 at 15 MTU/year is real.
South African licensing timeline is multi-year and unpredictable.
HALEU market pricing could compress if Centrus, Orano, or other Western capacity scales faster.
QLE spin timing and terms uncertain, dilution and market conditions matter.
Execution risk on Pelindaba construction, financing, and ramp-up.
SEQH View
ASPI is evolving from a single-entity story into a “stable isotope OpCo + QLE royalty/holdco” structure. The TerraPower contract alone provides a 2.7–3.0 billion dollar anchor that de-risks QLE’s initial commercialization phase. ASPI’s embedded value from this single contract, via royalty and retained equity, covers a significant portion of its current market cap before accounting for the core isotope business. Investors should view ASPI as a book of asymmetric call options on the HALEU market layered on top of a high-margin, near-term isotope cash flow engine.
Want the Full Options-Book Analysis?
[READ THE COMPLETE QLE / HALEU REPORT]
The full report includes proprietary analysis unavailable elsewhere:
Complete QLE capital stack walkthrough with post-spin economic waterfall to ASPI shareholders
Pelindaba facility pro-forma P&L with QE cost stack vs. NIA centrifuge baseline
TerraPower contract NPV modeling across multiple EBIT margin and discount rate scenarios
HALEU TAM sizing with NIA, NEI, and DOE demand projections mapped against QLE capacity
Embedded value framework: royalty NPV + retained equity valuation under bear/base/bull
Option-style payoff diagrams for ASPI’s royalty (perpetual revenue call) and equity (levered TAM call)
Sensitivity analysis: gross profit vs. HALEU price and contract NPV vs. discount rate
Competitive positioning vs. Centrus, SILEX, and Orano on HALEU cost curve
This is the only report that structures ASPI’s HALEU exposure as a quantifiable options book. If you’re sizing ASPI or QLE, this framework changes how you think about the position.
Available exclusively to SEQH Capital Research paid subscribers. Upgrade to access →
